
==== Front
Eur J Microbiol Immunol (Bp)
Eur J Microbiol Immunol (Bp)
EUJMI
European Journal of Microbiology & Immunology
2062-509X
2062-8633
Akadémiai Kiadó Budapest

39178045
10.1556/1886.2024.00072
Article
Antifungal potential, mechanism of action, and toxicity of 1,4-naphthoquinone derivatives
de Almeida Juan Diego Ribeiro 1 2
Fonseca Raissa Sayumy Kataki 1 2
de Sousa Naira Sulany Oliveira 2
Cortez Ana Cláudia Alves 2
Lima Emerson Silva 3
de Souza Oliveira Juliana Gomes 4
de Souza Érica Simplício 1 5
Frickmann Hagen 6 7
https://orcid.org/0000-0002-3163-7499
de Souza João Vicente Braga 2 * joaovicentebragasouza@yahoo.com.br

1 Postgraduate Program in Biotechnology and Natural Resources of the Amazon, Higher School of Health Sciences, Amazonas State University (UEA), Manaus, Amazonas, Brazil
2 Mycology Laboratory, National Institute for Amazonian Research (INPA), Manaus, Amazonas, Brazil
3 Faculty of Pharmaceutical Sciences, Federal University of Amazonas (UFAM), Manaus, Amazonas, Brazil
4 Collection of Microorganisms of Medical Interest, National Institute for Amazonian Research (INPA), Manaus, Amazonas, Brazil
5 Higher School of Technology, Amazonas State University (UEA), Manaus, Amazonas, Brazil
6 Institute for Medical Microbiology, Virology and Hygiene, University Medicine Rostock, Rostock, Germany
7 Department of Microbiology and Hospital Hygiene, Bundeswehr Hospital, Germany
* Corresponding author. Mycology Laboratory. National Institute for Amazonian Research, Av. André Araújo, 2936 – Petrópolis, CEP: 69060-001, Manaus, Amazonas, Brazil. Tel.: +55 (92) 3643 3055/3056. E-mail: joaovicentebragasouza@yahoo.com.br
23 8 2024
9 2024
14 3 289295
20 6 2024
06 8 2024
© 2024 The Author(s)
2024
The Author(s)
https://creativecommons.org/licenses/by-nc/4.0/ Open Access statement. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium for non-commercial purposes, provided the original author and source are credited, a link to the CC License is provided, and changes – if any – are indicated.

Abstract

Background

The rising prevalence of fungal infections and challenges such as adverse effects and resistance against existing antifungal agents have driven the exploration of new antifungal substances.

Methods

We specifically investigated naphthoquinones, known for their broad biological activities and promising antifungal capabilities. It specifically examined the effects of a particular naphthoquinone on the cellular components of Candida albicans ATCC 60193. The study also assessed cytotoxicity in MRC-5 cells, Artemia salina, and the seeds of tomatoes and arugula.

Results

Among four tested naphthoquinones, 2,3-DBNQ (2,3-dibromonaphthalene-1,4-dione) was identified as highly effective, showing potent antifungal activity at concentrations between 1.56 and 6.25 μg mL−1. However, its cytotoxicity in MRC-5 cells (IC50 = 15.44 µM), complete mortality in A. salina at 50 μg mL−1, and significant seed germination inhibition suggest limitations for its clinical use.

Conclusions

The findings indicate that primary antifungal mechanism of 2,3-DBNQ might involve disrupting fungal membrane permeability, which leads to increased nucleotide leakage. This insight underscores the need for further research to enhance the selectivity and safety of naphthoquinones for potential therapeutic applications.

Keywords

antifungal potential
naphthoquinone derivatives
2,3-DBNQ
fungal membrane permeability
cytotoxicity
Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES)
==== Body
pmcIntroduction

Fungi with pathogenic potential for humans have been increasingly recognized as etiologically relevant for severe infections in a growing number of both immunocompromised and immunocompetent patients in recent years. Primarily, this increase has been attributed to a rise in patients with acquired immunosuppression due to agents like the human immunodeficiency virus (HIV) and in those who develop neutropenia in response to chemotherapy [1]. Although antifungal resistance is already a well-recognized issue of concern, most attention and public resources remain focused on researching and developing new drugs against multidrug-resistant bacteria [2].

Nevertheless, the global emergence of multidrug-resistant fungi, such as certain lineages of Candida auris, has heightened alertness in clinical settings [3]. In particular, the ability of C. auris to spread rapidly among ill patients and in critical care units, as well as its propensity to develop resistance to the main classes of antifungal agents, including azoles (i.e., fluconazole), polyenes (amphotericin B), and echinocandins, makes its clinical management challenging and calls for strict infection control measures upon its detection [4–6].

Naphthoquinones are molecules in the quinone class with two aromatic rings forming their chemical backbone. They are synthesized by various plant families (Bignoniaceae, Ebenaceae, Droseraceae, Juglandaceae, Plumbaginaceae, Boraginaceae, among others) and can also be found as secondary metabolites in various algae, fungi, bacteria, and even some animals [7]. These molecules exhibit significant biological activities, such as antibacterial, antiviral, antioxidant, antiparasitic, cytotoxic, and antifungal properties [8]. The antifungal potential of semi-synthetic naphthoquinones was evaluated against 89 fungal isolates, and a compound named IVS320 was shown to be particularly promising. Specifically, it demonstrated best minimum inhibitory concentration (MIC) values for all tested cultures, primarily for Candida species and dermatophytes [9].

This study aimed to evaluate the antifungal potential of four naphthoquinones against fungal reference isolates (Candida spp., Sporothrix spp., Trichophyton spp., and Fusarium spp.), to determine their cytotoxic profile in MRC-5 human fibroblast cells, to assess toxicity using Artemia salina, and to examine phytotoxicity in tomato (Solanum lycopersicum) and arugula (Eruca sativa) seeds. Additionally, the study investigated the mechanism of action of the naphthoquinone derivate with the best antifungal efficacy against Candida albicans ATCC 60193.

Materials and methods

Naphthoquinones

In this study, we utilized the following naphthoquinones: lapachol (4-hydroxy-3-(3-methylbut-2-enyl)naphthalene-1,2-dione), 2-methoxynaphthalene-1,4-dione (2-MNQ), 2,3-dibromonaphthalene-1,4-dione (2,3-DBNQ), and 2-chloro-3-(2-fluoroanilino)naphthalene-1,4-dione (2-ClFNQ) as shown in Fig. 1. These compounds were obtained from Sigma-Aldrich (St. Louis, Missouri, USA). Stock solutions were prepared at a concentration of 3.2 mg mL−1 and further diluted in RPMI-1640 medium (Roswell Park Memorial Institute) (Sigma-Aldrich, St. Louis, Missouri, USA) to achieve the desired concentrations ranging from 1.56 to 800 μg mL−1 for the assays.

Fig. 1. Naphthoquinones derived from 1,4-naphthoquinone investigated in the present study

Microorganisms

Eleven reference strains from the “Collection of Microorganisms of Medical Interest” at the National Institute for Amazonian Research (INPA - Instituto Nacional de Pesquisas da Amazônia) were used (Table 1). Subcultures were grown in Sabouraud dextrose (KASVI, Madrid, Spain) medium to maintain purity and viability until testing.

Table 1. Reference microorganisms deposited in the Collection of Microorganisms of Medical Interest of the National Institute for Amazonian Research – INPA

Microorganisms	Species	Strain designation	
Yeasts	Candida albicans	ATCC 60193	
Candida albicans	ATCC 36323	
Candida krusei	ATCC 34135	
Candida tropicalis	ATCC 13803	
Candida glabrata	ATCC 2001	
Candida parapsilosis	ATCC 22019	
Subcutaneous pathogenic fungi	Sporothrix brasiliensis	CFP 00551	
Sporothrix schenckii	CFP 00746	
Dermatophytes	Trichophyton mentagrophytes	ATCC 9533	
Trichophyton rubrum	ATCC 28189	
Opportunistic filamentous fungi	Fusarium oxysporum	LM 5643	
ATCC = American type culture collection.

Antifungal activity assays

The assays applied to determine MIC values were based on the broth microdilution method as outlined in Clinical and Laboratory Standards Institute documents (CLSI) [10, 11]. Briefly, 100 µL of the test substance solutions, diluted in RPMI-1640 (Sigma-Aldrich, St. Louis, Missouri, USA) broth, were dispensed into 96-well microplates. Final concentrations ranged from 1.56 to 800 μg mL−1 for naphthoquinones (NQ), 0.125–64 μg mL−1 for fluconazole (FLU), and 0.0313–16 μg mL−1 for amphotericin B (AmB), both from Sigma-Aldrich (St. Louis, Missouri, USA). An additional, 100 µL of inoculum, containing 2.5 × 10³ cells/mL of yeasts or 2.5 × 10⁴ cells/mL of dermatophytes and opportunistic filamentous agents, were added. The plates were incubated at 35 °C for 24 h for yeasts and for 96 h for dermatophytes and opportunistic filamentous agents. Visual readings were taken after the incubation periods. The MIC was defined as the lowest concentration of naphthoquinones necessary to inhibit 100% of fungal growth compared to the control assay (performed without antifungal substances). After MIC determination, 10 µL aliquots from wells showing no visible fungal growth were inoculated onto Sabouraud dextrose (KASVI, Madrid, Spain) medium to determine the minimum fungicidal concentration (MFC) [12].

Antifungal mechanism of action

Sorbitol protection assay

The MIC of 2,3-DBNQ against C. albicans ATCC 60193 was determined according to CLSI guidelines (1.56–800 μg mL−1), both in the absence and presence of 0.8M sorbitol (Sigma-Aldrich, St. Louis, Missouri, USA), serving as an osmotic stabilizer. MICs were evaluated after 24 h of incubation at 35 °C [9].

Ergosterol effect assay

The MIC of 2,3-DBNQ against C. albicans ATCC 60193 was established following CLSI protocols, similar to previous descriptions, in the absence and presence of various concentrations (200–1600 μg mL−1) of ergosterol (Sigma-Aldrich, St. Louis, Missouri, USA). Amphotericin B (Sigma-Aldrich, St. Louis, Missouri, USA) was used as the reference antifungal drug in this assay. MICs were assessed after 24 h of incubation at 35 °C [9].

Extravasation assay for substances absorbing in the 260 nm spectrum

C. albicans ATCC 60193 cells were cultured under agitation at 35 °C until reaching the early stationary growth phase (18 h of growth) in RPMI medium (Sigma-Aldrich, St. Louis, Missouri, USA). Post-incubation, cells were washed and resuspended in 3-(N-morpholino)propanesulfonic acid (MOPS) buffer (0.16M, pH 7.0) (Sigma-Aldrich, St. Louis, Missouri, USA). Microtubes (final volume 1,500 µL) containing the inoculum (3 × 107 cells/mL) and 2,3-DBNQ (at 1× and 4× MIC) were incubated for 2, 4, and 24 h. After the incubation periods, the microtubes were centrifuged at 3,000 g for 5 min using a MiniSpin microcentrifuge (Eppendorf, Hamburg, Germany), and the absorbance of the supernatants (100 µL) was measured at 260 nm using a Gene Quant DNA/RNA spectrophotometer (Eppendorf, Hamburg, Germany). In this assay, 100% extravasation was defined as the absorbance measured with cells treated with SDS (sodium dodecyl sulfate, 2%) (Sigma-Aldrich, St. Louis, Missouri, USA) [13].

Toxicity assays

Due to the significant antifungal potential exhibited by 2,3-DBNQ and 2-MNQ, as detailed in the results section, their toxicity was further evaluated in the microcrustacean A. salina. Additionally, the phytotoxic and cytostatic potential of 2,3-DBNQ was assessed in S. lycopersicum (tomato) and E. sativa (arugula) seeds. All four naphthoquinones were tested in cell viability assays using the MRC-5 human fibroblast cell line.

MRC-5 cell line toxicity assay

This assay followed the protocol established by Ansar Ahmed et al. [14], aiming to analyze cell viability in MRC-5 fibroblast cells after a 24-h exposure to the substance of interest. Cells were seeded in 96-well plates at a density of 0.5 × 104 cells per well. Following a 24-h period for incubation and cell adhesion, they were treated with various concentrations of naphthoquinones (1.56–100 µM). Subsequently, 10 µL of alamarBlue® Cell Viability Reagent (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was added (0.4% stock solution diluted 1:20 in culture medium). After a 3-h period for resazurin metabolization, fluorescence was measured using a microplate reader to quantify cell viability.

Artemia salina toxicity assay

The protocol for this assay followed the guidelines set by Meyer et al. [15]. A. salina cysts were incubated in sterilized synthetic seawater (36 g L−1 marine salt – Ocean Tech Reef Salt, Ocean Technologies Group, London, England) under constant illumination at 28 °C. After 48 h, the hatched nauplii were transferred to 24-well plates. Due to their promising MIC values in the antifungal assay, the naphthoquinones 2,3-DBNQ and 2-MNQ were tested. Stock solutions of the naphthoquinones were prepared at 1 mg mL−1 in 5% DMSO (Merck KGaA, Darmstadt, Germany) and synthetic seawater, then serially diluted (1,000, 500, 300, 100, and 50 μg mL−1) and tested in triplicate. Ten nauplii were used per well, with 5% DMSO and synthetic seawater as controls. After 24 h, survival rates were assessed to determine the LC50 (Lethal Concentration 50), using PoloPlus software (version 1.0, LeOra Software LLC, Parma, MO, USA).

Germination inhibition assay in tomato and arugula seeds

For tomato seeds, a modified protocol by Sánchez Perera et al. [16], was employed. Seeds were placed in Petri dishes lined with sterile filter paper and exposed to various concentrations of 2,3-DBNQ (0–800 μg mL−1) in a solution of 10% DMSO (Merck KGaA, Darmstadt, Germany) and sterile distilled water. The final volume was 3 mL. The procedure for Arugula seeds was based upon the protocol described by Chouychai et al. [17]. Thereby, five seeds per dish were covered with different concentrations of 2,3-DBNQ (0–600 μg mL−1) in a similar diluent, with a final volume of 3 mL. In both cases, dishes were sealed to maintain humidity and incubated for 168 h at 25–27 °C. Post-incubation, seed germination and root length were evaluated, and germination rates were calculated using the following formula:I. % Growth=(root length with treatment / root length without treatment) x 100

II. % Inhibition=100 − % Growth

The assay's effectiveness was categorized as follows: moderately active (+) if 0<%I<29%; active (++) if 30<%I<59%; and highly active (+++) if 60<%I<100%.

Statistical analysis

Results were reported as mean ± standard deviation (SD) from three independent experiments, each conducted in triplicate, when necessary. Statistical differences (P < 0.05) in cytotoxicity tests were determined using analysis of variance (ANOVA), followed by Tukey's or Bonferroni's post-tests in GraphPad Prism 6.0 for Windows (GraphPad, San Diego, CA).

Ethics statement

Our study used standard organisms and substances, with all procedures complying with Brazilian regulations and international ethical standards, including the Declaration of Helsinki. No human or animal subjects were involved, so ethical approval was not required.

Results

Antifungal activity

To assess the antifungal potential of naphthoquinones, we determined the MICs of lapachol, 2-MNQ, 2,3-DNBQ, and 2-CIFNQ against 11 well-characterized reference strains of fungi with etiological relevance in human infections. These strains comprised opportunistic yeasts, dermatophytes, subcutaneous pathogenic fungi, and opportunistic filamentous fungi (Table 1). Among the compounds tested, 2-MNQ, 2,3-DNBQ and 2-CIFNQ exhibited antifungal activity, with 2,3-DBNQ showing the most promising effects, particularly against Candida species (MIC ranging from <1.56 to 6.25 μg mL−1) and dermatophytes (MIC <1.56 μg mL−1) (Table 2).

Table 2. Minimum inhibitory concentrations (MIC) of 100% as measured with the assessed 1–4 naphthoquinone derivatives for well-characterized strains of selected fungal species with etiological relevance for human patients

Microorganisms	Strain designation	Lapachol	2-MNQ	2,3-DNBQ	2-ClFNQ	AmB	FLU*	
Minimum Inhibitory Concentration (MIC) µg mL−1	
Candida albicans	ATCC 60193	>800	25	3.125	200	2	2	
ATCC 36232	>800	12.5	<1.56	100	2	2	
Candida krusei	ATCC 34135	>800	12.5	<1.56	50	4	16	
Candida tropicalis	ATCC 13803	>800	12.5	3.125	200	4	2	
Candida glabrata	ATCC 2001	>800	25	6.25	400	4	2	
Candida parapsilosis	ATCC 22019	>800	6.25	<1.56	100	2	2	
Sporothrix brasiliensis	CFP 00551	>800	50	3.125	25	2	64	
Sporothrix schenckii	CFP 00746	>800	25	3.125	12.5	8	64	
Trichophyton mentagrophytes	ATCC 9533	>800	6.25	<1.56	25	8	16	
Trichophyton rubrum	ATCC 28189	>800	<1.56	<1,56	50	2	2	
Fusarium oxysporum	LM 5634	>800	50	<1.56	100	16	32	
*Minimum inhibitory concentration (MIC) of 50%. AmB: Amphotericin B, FLU: Fluconazole.

So, the results of this study confirmed the considerable antifungal potential of naphthoquinones against fungi that are etiologically relevant to human health, including opportunistic yeasts, dermatophytes, subcutaneous pathogenic fungi, and opportunistic filamentous fungi. In detail, 2,3-DBNQ showed a fungicidal effect in several tested strains, highlighting a promising role of naphthoquinones, especially of 2,3-DBNQ, in the development of new antifungal agents.

Consequently, we further investigated the fungicidal and/or fungistatic properties of the test substance 2,3-DBNQ. Remarkably, 2,3-DBNQ exhibited a fungicidal profile for seven out of the ten tested strains, including Candida krusei, Candida tropicalis, Candida parapsilosis, Sporothrix brasiliensis, Sporothrix schenckii, Trichophyton mentagrophytes, and Fusarium oxysporum. In contrast, 2-MNQ and 2-ClFNQ showed fungicidal activity against four and six strains, respectively.

Mechanisms of action of 2,3-DBNQ

Due to the demonstrated antifungal potential of 2,3-DBNQ, it was selected for further evaluation of its potential mechanisms of biological action. The assessments included assays to examine the interaction of this antifungal compound with the organism's cell wall, cell wall ergosterol, and potential cellular leakage.

The sorbitol protection assay aimed at determining whether 2,3-DBNQ affects the integrity of the fungal cell wall. MIC assessments of 2,3-DBNQ against C. albicans ATCC 60193 were performed in parallel, both in the presence and absence of sorbitol (0.8M), an osmotic protectant used to stabilize fungal protoplasts. The MIC of 2,3-DBNQ remained unchanged in the presence of sorbitol (6.25 μg mL−1) after 24 h of incubation, suggesting that 2,3-DBNQ does not target mechanisms controlling the synthesis or integrity of the fungal cell wall.

To determine whether 2,3-DBNQ affects membrane ergosterol, an ergosterol assay was conducted. This test evaluates whether a compound interacts with ergosterol in the fungal cell membrane by introducing exogenous ergosterol. The results indicated that the MIC of 2,3-DBNQ against C. albicans ATCC 60193 cells did not change in the presence of various concentrations (200–1600 μg mL−1) of exogenous ergosterol, suggesting that 2,3-DBNQ does not significantly interact with ergosterol, a crucial component of the fungal cell membrane (Fig. 2).

Fig. 2. Influence of exogenous ergosterol on the MIC (Minimum Inhibitory Concentration) of 2,3-DBNQ (2,3-dibromonaphthalene-1,4-dione) when applied with Candida albicans ATCC 60193.

Axis X represents the two-folding concentrations of exogenous ergosterol in µg mL−1, while axis Y represents how many times the MIC value of the selected naphthoquinone against Candida albicans ATCC 60193 has been altered due to interaction with exogenous ergosterol. Amphotericin B its known for interact with ergosterol, as observed in the graph

Lastly, we explored whether 2,3-DBNQ induces cellular leakage, resulting in the efflux of nucleotides absorbing at 260 nm from C. albicans ATCC 60193 cells. Concentrations of 2,3-DBNQ at 3.25 μg mL−1 (1× MIC) and 12.5 μg mL−1 led to leakage ranging from 6% to 55.2% after 2, 4, and 24 h (Fig. 3), as compared to the positive control.

Fig. 3. Percentage of nucleotide extravasation in Candida albicans ATCC 60193 treated with 1× and 4× MIC (Minimum Inhibitory Concentration) of 2,3-DBNQ (2,3-dibromonaphthalene-1,4-dione). SDS (sodium dodecyl sulfate) 2% was used as positive control.

Axis X represents the time of reading of the experiment in hours, while axis y represents the percentage of cell leakage detected in 260 nm caused by the selected naphthoquinone in Candida albicans ATCC 60193. As observed, when treated with 4× MIC value (25 μg mL−1) cell leakage rises up to 55.6% in 24 h

Toxicity assays

We selected 2-MNQ and 2,3-DBNQ, identified for their notable antifungal activity, for toxicity evaluations using a human fibroblast cell line (MRC-5), the microcrustacean A. salina, and seeds of S. lycopersicum and E. sativa.

In the toxicity assessment using the human fibroblast cell line (MRC-5), 2-MNQ, 2,3-DBNQ, and 2-ClFNQ exhibited IC50 (Half-maximal inhibitory concentration 50) values of 11.9 µM, 15.4 µM, and 29.2 µM, respectively. Lapachol demonstrated low toxicity, with its IC50 value being undetectable under the experimental conditions.

We also investigated the toxicity of 2-MNQ and 2,3-DBNQ with A. salina. At a concentration of 50 μg mL−1, 2-MNQ caused 63% mortality, while 2,3-DBNQ resulted in 100% mortality. Additionally, we examined the toxicity of 2,3-DBNQ on seeds of S. lycopersicum and E. sativa. At a concentration of 400 μg mL−1, 2,3-DBNQ inhibited S. lycopersicum germination by 64.1%, and at 200 μg mL−1, it caused a 94.1% inhibition of E. sativa germination.

Furthermore, 2,3-DBNQ exhibited dose-dependent lethal effects on A. salina and inhibited the germination of S. lycopersicum and E. sativa seeds. These findings are well in line with the above-mentioned finding that 2-MNQ and 2,3-DBNQ demonstrated moderate cytotoxicity in the human fibroblast cell line.

Discussion

The antifungal properties of naphthoquinones are well documented in the scientific literature. Recent studies [18, 19] demonstrate that these compounds possess a broad spectrum of biological activities, including antifungal, antibacterial, antiviral, and antiparasitic effects [8]. The antifungal efficacy of naphthoquinones is attributed to their redox properties, which facilitate interactions with critical cellular components such as enzymes and fungal DNA [20]. Additionally, the structure-activity relationship of naphthoquinones varies according to the substituents attached to the naphthoquinone ring [21].

Furthermore, previous studies highlight the importance of the 2,3-disubstitution pattern in enhancing antifungal activity [22]. Our findings confirm the potent antifungal efficacy of 2,3-DBNQ and emphasize its potential as a promising candidate for the development of new antifungal agents.

Moving on to the mechanisms of action, the molecular mechanisms of naphthoquinone activity against fungi are not fully understood, but it is believed that they involve multiple targets, including the fungal cell wall, the cellular membrane and intracellular components. Our results indicate that 2,3-DBNQ induces cellular leakage in C. albicans ATCC 60193 cells, suggesting a possible mechanism of action by disrupting membrane permeability, in turn leading to the leakage of intracellular components. This finding is consistent with previous studies [9, 19] suggesting that naphthoquinones can cause oxidative damage due to the production of reactive oxygen species (ROS).

However, one of the main challenges for the clinical use of naphthoquinones is their toxicity, which has been extensively documented in the literature [23, 24]. These compounds have shown various toxic effects, including cytotoxicity, genotoxicity, and mutagenicity [25]. The toxicity of naphthoquinones is associated with their redox properties and their ability to generate ROS, which can cause oxidative damage to cellular components [26].

Despite these challenges, the significant antifungal potential of naphthoquinones, particularly 2,3-DBNQ, provides a solid foundation for further investigations on their applications in treating fungal infections. Future research should focus on elucidating the exact molecular mechanisms underlying the cellular leakage induced by 2,3-DBNQ, as well as on identifying potential synergistic interactions with existing antifungal agents. Additionally, evaluating the efficacy of naphthoquinones in in-vivo infection models and exploring their safety profile in animal studies will be essential steps toward developing novel antifungal therapeutics based on these compounds.

Conclusions

In summary, this study highlights the considerable antifungal properties of naphthoquinones, with 2,3-DBNQ showing the most notable activity against fungi relevant to human patients, including Candida species and dermatophytes. Our findings contribute to the growing body of evidence supporting the potential of naphthoquinone-based antifungal agents, given their broad biological activities and diverse potential modes of action. Further research into the precise molecular mechanisms and optimal applications of these compounds is necessary, as they could offer a valuable addition to the arsenal of antifungal therapies, addressing the persistent challenge of drug-resistant fungal infections.

Funding sources: This work was supported by the Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM) for the funding of the research (EDITAL N. 010/2021- CT&I ÁREAS PRIORITÁRIAS and EDITAL N. 006/2019 – UNIVERSAL AMAZONAS and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) (Finance code 001).

Authors' Contributions: Contributions to the study were as follows: JDRA – study concept and design, investigation, analysis and interpretation of data, manuscript writing, statistical analysis; RSKF – validation of data, statistical analysis; NSOS – writing – review and editing; ACAC – validation of data; ESL – investigation; JGSO – investigation, writing – review and editing; JVBS – study concept and design, investigation, analysis and interpretation of data, manuscript writing, supervision, funding acquisition, approval of final version; ESS – writing – review and editing, formal analysis, supervision, approval of final version; HF – writing – review and editing, approval of final version.

Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be interpreted as a potential conflict of interest.
==== Refs
References

1. Ozturk I, Tunçel A, Yurt F, Biyiklioglu Z, Ince M, Ocakoglu K. Antifungal photodynamic activities of phthalocyanine derivatives on Candida albicans. Photodiagnosis Photodyn Ther. 2020;30 :101715.32165338
2. Hendrickson JA, Hu C, Aitken SL, Beyda N. Antifungal resistance: a concerning trend for the present and future. Curr Infect Dis Rep. 2019;21 :1–8.30673882
3. Harris E. CDC: Candida auris fungal infections and drug resistance on the rise. JAMA. 2023;329 (15 ):1248–1248.
4. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73 (4 ):891–899.29325167
5. Forsberg K, Woodworth K, Walters M, Berkow EL, Jackson B, Chiller T, et al . Candida auris: the recent emergence of a multidrug-resistant fungal pathogen. Med Myco. 2019;57 (1 ):1–12.
6. Lockhart SR. Candida auris and multidrug resistance: defining the new norma. Fungal Genet Biol. 2019;131 :103243.31228646
7. Labbozzetta M, Poma P, Occhipinti C, Sajeva M, Notarbartolo M. Antitumor effect of Glandora rosmarinifolia (Boraginaceae) essential oil through inhibition of the activity of the topo II enzyme in acute myeloid leukemia. Molecules. 2022;27 (13 ):4203.35807446
8. Aminin D, Polonik S. 1,4-Naphthoquinones: some biological properties and application. Chem Pharm Bull. 2020;68 (1 ):46–57.
9. Ferreira M do PSBC, Cardoso MF do C, da Silva F de C, Ferreira VF, Lima ES, Souza JVB. Antifungal activity of synthetic naphthoquinones against dermatophytes and opportunistic fungi: preliminary mechanism-of-action tests. Ann Clin Microbiol Antimicrob. 2014;13 (1 ):1–6.24383440
10. CLSI. M27-A4. Reference method for broth dilution antifungal susceptibility testing of yeasts. Clin Lab Stand Institute; 2017a; 4th ed.
11. CLSI. M38-A4. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Clin Lab Stand Institute; 2017b; 4th ed.
12. Bona EAM De, Pinto FG da S, Fruet TK, Jorge TCM, Moura AC de. Comparação de métodos para avaliação da atividade antimicrobiana e determinação da concentração inibitória mínima (cim) de extratos vegetais aquosos e etanólicos. Arq Inst Biol. 2014;81 (3 ):218–225.
13. Escalante A, Gattuso M, Pérez P, Zecchino S. Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from Phytolacca tetramera Hauman. J Nat Prod. 2008;71 (10 ):1720–1725.18816139
14. Ansar Ahmed S, Gogal RM, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994;170 (2 ):211–224.8157999
15. Meyer BN, Ferrigni NR, Putnam E, Jacobsen LB, Nichols DE, Mclaughlin J L. Brine shrimp: a convenient general bioassay for active plant constituents. Planta Med. 1982;45 (1 ):31–34.
16. Sánchez Perera LM, Mancebo Dorvigny B, Regalado Veloz AI. Inhibition of seed germination, toxicity on Artemia salina and phytochemical prospecting with from Cuban plants as indicator of antitumo activity. Maced Pharma Bull. 2018;63 (2 ):29–36.
17. Chouychai W, Thongkukiatkul A, Upatham S, Lee H, Pokethitiyook P, Kruatrachue M. Phytotoxicity assay of crop plants to phenanthrene and pyrene contaminants in acidic soil. Environ Toxicol. 2007;22 (6 ):597–604.18000845
18. Vaezi A, Moghadaszadeh M, Nasri E, Gharibi S, Diba K, Matkowski A, et al. In vitro activity of juglone (5-hydroxy-1,4-naphthoquinone) against both fluconazole-resistant and susceptible Candida isolates. Revi Iberoam Micol. 2022;39 (2 ):50–53.
19. Yang J, Xia X, Guo M, Zhong L, Zhang X, Duan X, et al. 2-Methoxy-1,4-naphthoquinone regulated molecular alternation of Fusarium proliferatum revealed by high-dimensional biological data. RSC Adv. 2022;12 (24 ):15133–15144.35702436
20. López V, Les F. Fungal quinones: benzo-, naphtho-, and anthraquinones. In: Natural secondary metabolites. Cham: Springer International Publishing; 2023, pp. 607–626.
21. Futuro DO, Ferreira PG, Nicoletti CD, Borba-Santos LP, da Silva FC, Rozental S, et al. The antifungal activity of naphthoquinones: an integrative review. An Acad Bras Ciênc. 2018;90 (1 ):1187–1214.29873671
22. Sánchez-Calvo JM, Barbero GR, Guerrero-Vásquez G, Durán AG, Macías M, Rodríguez-Iglesias, MA, et al. Synthesis, antibacterial and antifungal activities of naphthoquinone derivatives: a structure–activity relationship study. Med Chem Res. 2016;25 (6 ):1274–1285.
23. de Almeida PDO, dos Santos Barbosa Jobim G, dos Santos Ferreira CC, Rocha Bernardes L, Dias RB, Schlaepfer Sales CB, et al. A new synthetic antitumor naphthoquinone induces ROS-mediated apoptosis with activation of the JNK and p38 signaling pathways. Chem Biol Interact. 2021;343 :109444.33939975
24. Mahalapbutr P, Leechaisit R, Thongnum A, Todsaporn D, Prachayasittikul V, Rungrotmongkol T, et al. Discovery of anilino-1,4-naphthoquinones as potent EGFR tyrosine kinase inhibitors: synthesis, biological evaluation, and comprehensive molecular modeling. ACS Omega. 2022;7 (21 ):17881–17893.35664590
25. Lima Bezerra JJ, Johanes I, Vieira Pinheiro AA. Anticancer potential and toxicity of the genus Handroanthus Mattos (Bignoniaceae): a systematic review. Toxicon. 2022;217 :131–142.35998713
26. Emadi A, Ross AE, Cowan KM, Fortenberry YM, Vuica-Ross M. A chemical genetic screen for modulators of asymmetrical 2,2′-dimeric naphthoquinones cytotoxicity in yeast. PLoS One. 2010;5 (5 ):e10846.20520766
